![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
TOP NEWS: AstraZeneca drug Tagrisso gets EU approval for cancer form
(Alliance News) - AstraZeneca PLC on Friday announced that its medication osimertinib, alongside chemotherapy, has been approved by the European Commission.
Read moreMon, 01st Jun 2015 13:49
(Alliance News) - AstraZeneca PLC on Friday announced that its medication osimertinib, alongside chemotherapy, has been approved by the European Commission.
Read more(Alliance News) - Aptamer Group PLC on Wednesday said it reached an agreement with AstraZeneca PLC.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:
Read more(Alliance News) - AstraZeneca PLC on Monday said two cancer treatments had been recommended for approval in the European Union, while there was also positive news for a Covid treatment.
Read more(Alliance News) - Stocks in London are called to open higher on Monday, at the start of a politically fuelled week.
Read more(Sharecast News) - AstraZeneca announced on Monday that 'Imfinzi', or durvalumab, and 'Lynparza', or olaparib, have received a recommendation for approval in the European Union (EU) as treatments for primary advanced or recurrent endometrial cancer in patients with specific genetic profiles.
Read moreFRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.
Read more(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.
Read more(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.
Read more(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.
Read more(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.
Read moreWASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.
Read moreWASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.
Read more(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.
Read more